Milestone

On May 12, 2025, GXCPC1^®, an allogeneic stem cell drug for treating knee osteoarthritis, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase III human clinical trial.

On March 20, 2025, GWOXI’s human adipose derived mesenchymal stem cell exosome was assigned an INCI Name (Mono ID: 37487) by the Personal Care Products Council (PCPC).

On December 9, 2024, it was announced that the draft clinical study report for the Phase I trial of GXIPC1® in the treatment of type 1 diabetes had been completed in Vietnam.

On November 19, 2024, GXCPC1®, an allogeneic stem cell drug for treating knee osteoarthritis, received the 2024 National Pharmaceutical Technology and Research Development Award (NPRDA) for the recognition of outstanding achievement.

On September 9, 2024, it was announced that an application for a Phase III clinical trial of GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, had been submitted to the Taiwan Food and Drug Administration (TFDA).

On September 6, 2024, it was announced that the clinical study report for the Phase II clinical trial of GXNPC1®, a stem cell therapy product for the treatment of chronic stroke, was acknowledged by the Taiwan Food and Drug Administration (TFDA).

On April 17, 2024, it was announced that GXIPC1®, an allogeneic stem cell therapy product for the treatment of type 1 diabetes, had completed patient enrollment for its Phase I trial at the Vinmec Research Institute of Stem Cell and Gene Technology (VRISG) in Vietnam.

On December 25, 2023, GXNPC1®, an autologous stem cell therapy product for the treatment of chronic stroke, was awarded the 2023 National Innovation Award - Excelsior Award in recognition of its continuing innovations and advancements.

On December 15, 2023, GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, was awarded the 2023 Hsinchu Science Park Innovative Product Award.

On October 23, 2023, GWOXI was received the 2022 Hsinchu County Local Industry Innovation and R&D Promotion Program (SBIR) - Outstanding Enterprise Award.

On October 2, 2023, GWOXI announced the Phase II clinical trial primary endpoint results for GXNPC1®, its autologous stem cell therapy product for the treatment of chronic stroke.

On July 11, 2023, GWOXI announced the Phase I/II clinical trial results for GXCPC1®, its allogeneic stem cell therapy product for the treatment of knee osteoarthritis.

T On April 26, 2023, GWOXI was approved for listing on the Emerging Stock Board of the Taipei Exchange (TPEx: 6704).

On March 2, 2023, it was announced that GXNPC1®, an autologous stem cell therapy product for the treatment of chronic stroke, had completed the patient enrollment for its Phase II trial.

On December 23, 2022, GXNPC1®, an autologous stem cell therapy product for the treatment of chronic stroke, was awarded the 2023 National Innovation Award - Excelsior Award in recognition of its continuing innovations and advancements.

On December 23, 2022, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was awarded the 2022 National Innovation Award - Excelsior Award in recognition of its continuing innovations and advancements.

On November 29, 2022, GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, received the 2022 National Pharmaceutical Technology and Research Development Award (NPRDA) - Bronze Award.

On November 16, 2022, GWOXI received the 2022 Hsinchu Science Park R&D Accomplishment Award.

On September 1, 2022, it was announced that GXIPC1®, an allogeneic stem cell therapy product for the treatment of type 1 diabetes, had completed the first stage of patient enrollment for its Phase I trial at the Vinmec Research Institute of Stem Cell and Gene Technology (VRISG) in Vietnam.

On September 1, 2022, GTESTing® Laboratory passed the extension assessment for TAF ISO/IEC 17025:2017;CNS 17025:2018 accreditation, conducted by the Taiwan Accreditation Foundation (TAF).

On April 28, 2022, GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, has completed the patient enrollment for its Phase I/II trial.

On December 17, 2021, GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was awarded the 18^th National Innovation Award in the Pharmaceutical and Precision Medicine Category.

On October 13, 2021, GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, enrolled its first subject in the Phase II clinical trial.

On October 5, 2021, GWOXI’s stem cell preparation facility had received the Green Building Label from the Taiwan Architecture and Building Center (TABC).

On July 28, 2021, GXIPC1®, an allogeneic stem cell therapy product for the treatment of type I diabetes, was approved to conduct the Phase I trial in Vietnam by the Ministry of Health of Vietnam.

On April 22, 2021, it was announced that GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, had completed the patient enrollment for its Phase I trial.

In April 2021, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was approved the A+ Corporate Innovation and R&D Program (Fast-Track Review for Clinical Trial Plans) under the Ministry of Economic Affairs in Taiwan.

On December 15, 2020, GXHPC1^®, an autologous stem cell therapy product for the treatment of liver cirrhosis, received the 2020 National Pharmaceutical Technology and Research Development Award (NPRDA) - Bronze Award.

On December 1, 2020, GXHPC1^®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was awarded the 2020 National Innovation Award - Excelsior Award in recognition of its continuing innovations and advancements.

On March 18, 2020, GXHPC1^®, an autologous stem cell therapy product for the treatment of liver cirrhosis, enrolled the first patient for its Phase II trial at National Taiwan University Hospital.

On February 20, 2020, GXNPC1^®, an autologous stem cell drug for the treatment of chronic stroke, enrolled the first patient for its Phase II trial at Hualien Tzu Chi Hospital.

The construction of stem cell preparation factory at Hsinchu Biomedical Science Park has been completed.

On December 6, 2019, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was awarded the 2019 National Innovation Award - Excelsior Award in recognition of its continuing innovations and advancements

On December 4, 2019, GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was awarded the 2019 International Innovation Awards® (IIA) in the Product Category.

On November 21, 2019, GTESTing® Laboratory passed the extension assessment for TAF ISO/IEC 17025:2017 accreditation, conducted by the Taiwan Accreditation Foundation (TAF).

On November 5, 2019, GWOXI signed a Memorandum of Understanding (MoU) with the Vinmec Research Institute of Stem Cell and Gene Technology (VRISG) to conduct a human clinical trial of stem cell therapy for diabetes and to jointly develop GXIPC1®, a stem cell medicine for the treatment of diabetes.

On September 11, 2019, GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase II human clinical trial.

On July 26, 2019, GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was awarded the 2019 Taipei Biotech Awards – Innovation Special Mention Award.

On July 26, 2019, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase II human clinical trial.

On January 3, 2019, GXCPC1®, an allogeneic stem cell therapy product for the treatment of knee osteoarthritis, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I/II human clinical trial.

On November 30, 2018, GWOXI was awarded the Certificate of Symbol of National Quality (SNQ) for its Quality Testing Services of Clinical Cellular Products in the Biomedical Enterprise Section / Medical Peripheral Category.

On November 30, 2018, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was awarded the 15th National Innovation Award in the Precision Medicine Category

On October 16, 2018, GWOXI was awarded Hsinchu Science Park Innovative Product Awards.

On October 15, 2018, GWOXI was awarded Hsinchu Science Park R&D Accomplishment Awards.

On October 4, 2018, GWOXI was certified as a Biotech and Pharmaceutical Company by the Ministry of Economic Affairs in Taiwan.

On May 21, 2018, GWOXI held a topping-out ceremony for its new constructed PIC/S GMP stem cell preparation facility at Hsinchu Biomedical Science Park.

On November 8, 2017, GTESTing® laboratory was awarded Exemaplary Model Award by the Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare.

On June 30, 2017, GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was awarded 2017 Taipei Biotech Awards – Innovation Special Mention Award.

GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I human clinical trial.

On December 22, 2016, GWOXI was awarded the Certificate of Symbol of National Quality (SNQ) for its Pharmaceutical-Grade Stem Cell Storage Service in the Biotechnology Service Category.

On November 18, 2016, GWOXI was awarded the 23^rd Taiwan Small and Medium Enterprise Innovation Award for its The Production Technology Platform of Pharmaceutical-Grade Adipose-Derived Stem Cell Products.

GXHPC1®, an autologous stem cell therapy product for the treatment of liver cirrhosis, was approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I human clinical trial.

GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, was certified under the Act for the Development of Biotech and Pharmaceutical Industry.

GWOXI was recognized as a Translational Model in Stem Cell and Regenerative Medicine under the Pilot Program for Training Translational Talent in Medicine and Agriculture by the Ministry of Education of Taiwan.

On October 17, 2013, GTESTing® Laboratory (accreditation number: 2800) was accredited by the Taiwan Accreditation Foundation (TAF) for ISO/IEC 17025:2005.

GXNPC1®, an autologous stem cell drug for the treatment of chronic stroke, has completed its preclinical study.

GXHPC1®, an autologous stem cell drug for the treatment of liver cirrhosis, was certified under the Act for the Development of Biotech and Pharmaceutical Industry.

GWOXI built its Stem Cell R&D Center and a GTP (Good Tissue Practice) Cell Processing Center at the Hsinchu Biomedical Science Park.

GWOXI developed a Special Protein for Activation as the active ingredient for a health supplement and published the results in an international journal.

GWOXI was approved by the National Science Council, Executive Yuan to move into the Hsinchu (Zhubei) Biomedical Science Park.

GWOXI started its development of stem cell therapy product for the treatment of liver cirrhosis/fibrosis.